Skip to main content
Home
Menu
  • About
  • Investments
  • FAQs
  • News
  • Contact
  • Menu
  • Login

You are here

Home

FSP Group Investor Alert: Symtomax keeps investors happy with major launch of new Oral Tabs CBD product

Cannabis cultivation business Symtomax have announced the launch of new CBD product Oral Tabs – featuring a revolutionary new method.

Find out more

Latest investor news & articles

01
Jul
What do David Beckham, John Travolta, Gary Numan, Vic Reeves and Keith Flint all have in common?
24
Jun
FSP Group Investor alert announces ground-breaking AirPods agreement and potentially huge deal for the US
13
Jun
FSP Group announces invite to investors to participate with TVR reboot and new Gordon Murray inspired Griffith

Stay ahead of the curve
Get the latest investment news and updates

Get the latest investment news, new opportunities, partnerships, and more. You can opt out anytime.

*Required info. We will never spam you and you can opt-out of our investor news anytime you choose. Check our privacy policy here

Frequently Asked Investor / Investment FAQs

If you have an questions about us or the investment products we offer, please don't hesitate to get in touch

What risk do I have to take to generate a good return on my money?

Our goal is to offer investments suited to your desired risk profile. We recommend that you always consult with a qualified independent financial advisor before proceeding with any investments.

How are investments taxed?

Different products are taxed in different ways and at different times of the year. Although we do not offer tax advice, we do take into account the tax-efficiency of any investment products we offer.

What are your office hours?

9:30AM - 6:00 PM Monday to Friday 10am - 2pm Saturday Evenings by appointment only (To make an appointment please call main reception on 0203 769 3080)

Menu
  • About
  • Investment Products
  • FAQs
  • News
  • Contact
  • Privacy
  • Terms
© Copyright The FSP Group 2023 - Global investment opportunities to stay ahead of the curve
  • About
  • Investment Products
  • FAQs
  • News
  • Contact